KLF5 Antibody, FITC conjugated

說(shuō)明書(shū)

中文名稱：

KLF5兔多克隆抗體, FITC偶聯(lián)
貨號(hào)：

CSB-PA613429LC01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) KLF5 Polyclonal antibody
Uniprot No.：

Q13887
基因名：

KLF5
別名：

Basic transcription element binding protein 2 antibody; Basic transcription element-binding protein 2 antibody; BTE binding protein 2 antibody; BTE-binding protein 2 antibody; BTEB 2 antibody; BTEB2 antibody; CKLF antibody; Colon krueppel like factor antibody; Colon krueppel-like factor antibody; GC box binding protein 2 antibody; GC-box-binding protein 2 antibody; IKLF antibody; Intestinal enriched krueppel like factor antibody; Intestinal-enriched krueppel-like factor antibody; KLF 5 antibody; Klf5 antibody; KLF5_HUMAN antibody; Krueppel like factor 5 antibody; Krueppel-like factor 5 antibody; Kruppel like factor 5 intestinal antibody; Transcription factor BTEB 2 antibody; Transcription factor BTEB2 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Krueppel-like factor 5 protein (69-346AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes.
基因功能參考文獻(xiàn)：
1. These results revealed that KLF5 promotes the tumorigenesis and metastasis of thyroid cancer cells and may be a potential therapeutic target in patients with thyroid cancer PMID: 30226614
2. the present findings were the first to show that KLF5 expression and nitration by iNOS-mediated peroxynitrite are necessary for the induction of TNF-alpha and IL-1beta expression in VSMCs of diabetic vascular tissues. PMID: 28711598
3. the results of the present study suggested that the miR5905p/KLF5 axis may regulate osteosarcoma (OS)progression and thus, may be a novel therapeutic target for the treatment of patients with OS. PMID: 29916536
4. Study showed that KLF5 expression was increased in intracranial aneurysms (IAs) patients compared to that of normal subjects, and KLF5 overexpression vascular smooth muscle cells proliferation, migration, and phenotypic modulation, suggesting that the upregulated KLF5 expression played an important role in the induction of IAs. PMID: 30201338
5. correlation between the KLF5 and ZEB1 transcription levels in the pancreatic tumor tissues PMID: 30168064
6. The present study has identified that KLF5, a target of miR-145-5p, is a key marker gene in cancer. miR-145-5p may also contribute to the dysregulation of other functional genes during tumor development. PMID: 29658584
7. the knockdown of HDAC1/2 upregulated KLF5 protein but not KLF5 mRNA, and the increase in KLF5 protein level by silencing HDAC1/2 was at least in part due to decreased proteasomal degradation. PMID: 29679567
8. KLF5 expression in tumor stroma was closely associated with clinicopathological features such as tumor size, invasion depth, cell grade and lymph node metastasis, as well as poor prognosis in patients with gastric cancer. PMID: 28934010
9. KLF5 has a role in regulating IL1beta induced intervertebral disc metabolism PMID: 29196238
10. Levels of KLF5 are increased in human pancreatic ductal adenocarcinoma. PMID: 29248441
11. Data demonstrate that KLF5 inhibits ccRCC growth as a tumor suppressor and highlight the potential of 5-Aza-CdR to release KLF5 expression as a therapeutic modality for the treatment of ccRCC. PMID: 28749461
12. The present study found that the KLF4 and KLF5 3'-UTR contains one conserved target site of miR-506 and miR-124, and the overexpression of miR-506 and miR-124 inhibited the H2O2-induced upregulation of KLF4 and KLF5 in HCMs. PMID: 28849090
13. miR-5195-3p suppressed proliferation and invasion of human bladder cancer cells via suppression of KLF5. PMID: 28109084
14. miR-217 suppresses triple-negative breast cancer cell growth, migration, and invasion. MiR-217 suppresses triple-negative breast cancer, at least partially, through down-regulating the KLF5 expression. PMID: 28437471
15. Data reveal that the presence of rs200996365, a SNP in high-linkage disequilibrium with rs8102137 residing in the center of a KLF5 motif, alters KLF5 binding to this genomic region and provide evidence that KLF5 binds CCNE1 polymorphic intronic enhancer to confer increased bladder cancer risk. PMID: 27514407
16. demonstrate that a 186bp region is the minimal essential region and that Sp3-GC1 binding is essential to the basal expression of KLF5 PMID: 27940107
17. We provide the first evidence that the expression of KLF5 is up-regulated in small airways and pulmonary vessels of patients with COPD and may be involved in the tissue remodeling of COPD. PMID: 26792671
18. our results indicate that KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription PMID: 26544730
19. Data indicate direct binding of microRNA miR-375 to the 3'-untranslated region of transcription factor KLF5. PMID: 26474386
20. findings collectively suggest that TNFAIP2 is a direct KLF5 target gene, and both KLF5 and TNFAIP2 promote breast cancer cell proliferation, migration and invasion through Rac1 and Cdc42 PMID: 26189798
21. KLF5/Sox4 regulatory signaling play an important role in lung tumorigenesis, which might represent novel therapeutic targets to manage lung carcinoma. PMID: 24401325
22. BAP1 interacts directly with KLF5 and stabilizes KLF5 via deubiquitination. PMID: 26419610
23. Data suggest both KLF5 and FYN (FYN proto-oncogene) are important in regulation of migration in bladder cancer cells; KLF5 up-regulates cell migration, lamellipodia formation, expression of FYN, and phosphorylation of FAK (focal adhesion kinase). PMID: 26786295
24. ATXN3L has a role in the regulation of KLF5 stability in breast cancer PMID: 26079537
25. TEAD4 and KLF5, in collaboration, promoted triple negative breast cancer cell proliferation and tumor growth in part by inhibiting p27 gene transcription PMID: 25970772
26. that estrogen biphasically modulates prostate tumor formation by regulating Kruppel-like zinc finger transcription factor 5-dependent transcription through estrogen receptor beta PMID: 26483416
27. down-regulation of KLF4 and up-regulation of KLF5 may stimulate oral carcinoma progression through the dedifferentiation of carcinoma cells. PMID: 26097551
28. KLF5 loss enhances tumor angiogenesis by attenuating PI3K/AKT signaling and subsequent accumulation of HIF1alpha in PTEN deficient prostate tumors. PMID: 25896712
29. KLF5 facilitates lysophosphatidic acid -induced interaction between beta-catenin and TCF4. PMID: 25683913
30. These results identify KLF4 and KLF5 as cooperating protumorigenic factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with conventional HER2-targeted therapies. PMID: 25789974
31. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. PMID: 25504335
32. TMEM16A and myocardin form a positive feedback loop that is disrupted by KLF5 during Ang II-induced vascular remodeling. PMID: 26077572
33. KLF5/GATA4/GATA6 may promote gastric cancer development by engaging in mutual crosstalk, collaborating to maintain a pro-oncogenic transcriptional regulatory network in gastric cancer cells. PMID: 25053715
34. Using small interfering RNA (siRNA) targeting KLF5 or HIF-1alpha, study demonstrated that KLF5 or HIF-1alpha knockdown inhibited hypoxia-induced cell survival and promoted cell apoptosis by actively downregulating cyclin B1, survivin and upregulating caspase-3 in lung cancer cells. PMID: 25051115
35. study results indicate that KLF5 mediates proinflammatory cytokine expression through upregulation of NF-kappaB phosphorylation at p65 in LPS-induced ALI. PMID: 25197166
36. KLF5 mRNA overexpression is associated with cervical cancer. PMID: 25119587
37. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kruppel-like factor 5 and nuclear factor-kappaB pathway PMID: 25023776
38. Data indicate that histone deacetylase inhibitors (HDACi) induce intestinal alkaline phosphatase (ALPi) in a subset of colon cancer cell lines in a Kruppel-like factor 5 (KLF5)-dependent manner. PMID: 25037223
39. deacetylation switched KLF5 to tumor promoting activity, and blocking TGFbeta signaling attenuated the tumor suppressor activity of KLF5 PMID: 24931571
40. Altogether, our data provide an explanation for low HK3 and KLF5 expression in particular AML subtype and establish these genes as novel CEBPA targets during neutrophil differentiation. PMID: 24584857
41. The differential roles of KLF5 in particular tissues and cancer states. [Review] PMID: 24323942
42. amino acid residue 301 of KLF5 is critical for proper recognition of the phosphodegron sequence by FBW7alpha and that the P301S mutation inhibits this recognition PMID: 24398687
43. Kruppel-like factor 5: a novel biomarker for lymph node metastasis and recurrence in supraglottic squamous cell laryngeal carcinoma. PMID: 23975368
44. KLF5 was highly expressed in the ovarian cancer cell line. PMID: 23869764
45. KLF5 maintains epithelial characteristics and prevents EMT by transcriptionally activating the miR-200 family in epithelial cells. PMID: 24126055
46. KLF5 is an androgen-responsive gene in breast carcinomas, which plays an important role in progression and is considered a potent prognostic factor in human breast cancers. PMID: 22936544
47. mPGES1 is a target gene of KLF5 in human breast cancer celsl PMID: 23913682
48. Data suggest that KLF5 activity is regulated by progesterone/estrogen in normal mammary gland and in breast cancer; KLF5 participates in estrogen/estrogen receptor and progesterone/progesterone receptor signaling and breast tumorigenesis. [REVIEW] PMID: 23810009
49. These results identify KLF5 as a transactivator of HIF-1alpha and show that LPA regulates HIF-1alpha by dynamically modulating its interaction with KLF5 and p53. PMID: 23880760
50. KLF5 activation of JNK signaling is mediated by KLF5 transactivation of two key upstream regulators of the JNK pathway, ASK1 and MKK4. PMID: 23633919
顯示更多

收起更多
亞細(xì)胞定位：

Nucleus.
蛋白家族：

Krueppel C2H2-type zinc-finger protein family
組織特異性：

Expressed only in testis and placenta.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6349

OMIM: 602903

KEGG: hsa:688

STRING: 9606.ENSP00000366915

UniGene: Hs.508234

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human